International Clinical Trial: Trial to Evaluate the Safety and Feasibility of Belzupacap Sarotalocan (AU-011) for the Treatment of Conjunctival Melanoma, Melanocytic Lesions, or Conjunctival Squamous Cell Carcinoma in adult participants

Geneva, April 28 -- International Clinical Trials Registry received information related to the study (ACTRN12626000465358) titled 'Trial to Evaluate the Safety and Feasibility of Belzupacap Sarotalocan (AU-011) for the Treatment of Conjunctival Melanoma, Melanocytic Lesions, or Conjunctival Squamous Cell Carcinoma in adult participants' on April 15.

Study Type: Interventional

Study Design: Purpose: Treatment Allocation: Non-randomised trial Masking: Open (masking not used) Assignment: Parallel Type of endpoint: Safety/efficacy

Primary Sponsor: Aura Biosciences, Inc.

Condition: Cancer of the ocular (eye) surface Conjunctival Melanoma Melanocytic Lesions Conjunctival Squamous Cell Carcinoma Cancer of the ocular (eye) surface Conjunct...